Unknown. Final rule

6,229 words·~28 min read·/register/2023/01/05/2022-28428

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

--- schema: federal-register doc_type: fedreg source_file: FR-2023-01-05.xml --- 88 3 Thursday, January 5, 2023 Contents Centers Disease Centers for Disease Control and Prevention NOTICES Requirements for Negative Pre-departure COVID-19 Test Results or Documentation of Recovery from COVID-19 for Aircraft Passengers Traveling to the United States from the People's Republic of China, 864-871 2023-00080 Coast Guard Coast Guard RULES Safety Zones: Corpus Christi Shipping Channel, Corpus Christi, TX, 756-758 2023-00071 NOTICES Meetings:

Great Lakes Pilotage Advisory Committee; February 2023, 878-879 2022-28636 Commerce Commerce Department See International Trade Administration See National Oceanic and Atmospheric Administration Education Department Education Department NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 860-861 2022-28620 Energy Department Energy Department PROPOSED RULES Energy Conservation Program: Test Procedure for Uninterruptible Power Supplies, 790-805 2022-27881 Environmental Protection Environmental Protection Agency RULES Air Quality State Implementation Plans;

Approvals and Promulgations: North Carolina; Miscellaneous New Source Review Revisions and Updates; Updates to References to Appendix W Modeling Guideline, 773-775 2022-28150 Finding of Failure to Attain and Reclassification of Las Vegas Area as Moderate for the 2015 Ozone National Ambient Air Quality Standard, 775-783 2022-28319 PROPOSED RULES National Emission Standards for Hazardous Air Pollutants: Lime Manufacturing Plants Amendments, 805-820 2022-27994 Farm Credit Farm Credit Administration NOTICES Meetings;

Sunshine Act, 861 2023-00074 Federal Aviation Federal Aviation Administration NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals: Airport Grants Program, 900-901 2022-28597 Federal Communications Federal Communications Commission RULES Annual Adjustment of Civil Monetary Penalties to Reflect Inflation, 783-786 2022-28493 Federal Deposit Federal Deposit Insurance Corporation NOTICES Civil Monetary Penalty Inflation Adjustment, 861-863 2022-28655 Federal Election Federal Election Commission NOTICES Meetings;

Sunshine Act, 863 2023-00090 Federal Motor Federal Motor Carrier Safety Administration PROPOSED RULES Broker and Freight Forwarder Financial Responsibility, 830-854 2022-28259 NOTICES Exemption Application: Qualification of Drivers; Epilepsy and Seizure Disorders, 904-908 2022-28608 2022-28630 Qualification of Drivers; Hearing, 901-904 2022-28627 2022-28628 Food and Drug Food and Drug Administration RULES Food Additives Permitted for Direct Addition to Food for Human Consumption:

Vitamin D3, 745-749 2022-28428 Medical Devices: Neurological Devices; Classification of the Brain Stimulation Programming Planning Software, 749-751 2022-28603 Orthopedic Devices; Classification of the Bone Indentation Device, 753-755 2022-28601 Orthopedic Devices; Classification of the Implantable Post-Surgical Kinematic Measurement Knee Device, 751-753 2022-28604 NOTICES Guidance: Format and Content of a Risk Evaluation and Mitigation Strategy Document, 871-873 2022-28602 General Services General Services Administration NOTICES Calendar Year 2023 Privately Owned Vehicle Mileage Reimbursement Rates;

Calendar Year 2023 Standard Mileage Rate for Moving Purposes, 864 2022-28592 Meetings: Senior Policy Operating Group's Procurement and Supply Chains Committee Outreach Session, 863-864 2022-28596 Health and Human Health and Human Services Department See Centers for Disease Control and Prevention See Food and Drug Administration See Health Resources and Services Administration PROPOSED RULES Safeguarding the Rights of Conscience as Protected by Federal Statutes, 820-830 2022-28505 Health Resources Health Resources and Services Administration NOTICES Agency Information Collection Activities;

Proposals, Submissions, and Approvals: Uniform Data System, 874-876 2022-28621 Bright Futures Periodicity Schedule; Preventive Services Guidelines for Infants, Children, and Adolescents, 873-874 2022-28661 Women's Preventive Services Guidelines Relating to Screening for Diabetes in Pregnancy and Screening for Diabetes after Pregnancy, 876-878 2022-28662 Homeland Homeland Security Department See Coast Guard Indian Affairs Indian Affairs Bureau NOTICES Agency Information Collection Activities;

Proposals, Submissions, and Approvals: Fiscal Year 2024 Expirations, 879-882 2022-28612 Interior Interior Department See Indian Affairs Bureau Internal Revenue Internal Revenue Service RULES Treatment of Special Enforcement Matters; Correction, 755-756 2022-28593 2022-28594 NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 910-911 2022-28640 2022-28641 International Trade Adm International Trade Administration NOTICES Antidumping or Countervailing Duty Investigations, Orders, or Reviews:

Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled into Modules, from the People's Republic of China, 856-858 2022-28639 Fresh Garlic from the People's Republic of China, 858-859 2022-28663 Stainless Steel Wire Rods from India, 855 2022-28614 International Trade Com International Trade Commission NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals, 882-883 2022-28591 Complaint, 883-884 2022-28610 Labor Department Labor Department See Mine Safety and Health Administration Mine Mine Safety and Health Administration NOTICES Petition:

Modification of Application of Existing Mandatory Safety Standards, 885-888 2022-28622 2022-28623 2022-28624 National Oceanic National Oceanic and Atmospheric Administration RULES Atlantic Highly Migratory Species: Atlantic Bluefin Tuna Fisheries; General Category January through March Quota Transfer, 786-788 2022-28635 Fisheries of the Exclusive Economic Zone off Alaska: Inseason Adjustment to the 2023 Bering Sea and Aleutian Islands Pollock, Atka Mackerel, and Pacific Cod Total Allowable Catch Amounts, 789 C1-2022-28343 Pacific Cod by Catcher Vessels Using Hook-and-Line Gear in the Western Regulatory Area of the Gulf of Alaska, 789 2022-28629 Fisheries of the Northeastern United States:

Atlantic Deep-Sea Red Crab Fishery; Final 2023 Atlantic Deep-Sea Red Crab Specifications, 788-789 2022-28626 PROPOSED RULES Taking and Importing Marine Mammals: Incidental to Geophysical Surveys in the Gulf of Mexico, 916-948 2022-28208 NOTICES Meetings: Mid-Atlantic Fishery Management Council, 859 2022-28660 New England Fishery Management Council, 859-860 2022-28659 Permits; Applications, Issuances, etc.: Endangered Species; File No. 27106; Correction, 859 2022-28553 Pension Benefit Pension Benefit Guaranty Corporation NOTICES Agency Information Collection Activities;

Proposals, Submissions, and Approvals: Multiemployer Plan Regulations, 888-890 2022-28609 Pipeline Pipeline and Hazardous Materials Safety Administration NOTICES Pipeline Safety; Special Permit: Columbia Gas Transmission, LLC, 908-909 2022-28654 East Tennessee Natural Gas Transmission, LLC, 909-910 2022-28653 Postal Service Postal Service RULES Removal of Sacks: USPS Marketing Mail and Periodicals Flats, 758-773 2022-28587 NOTICES Product Change: First-Class Package Service and Parcel Select Service Negotiated Service Agreement, 891 2022-28648 Parcel Return Service Negotiated Service Agreement, 891 2022-28651 Parcel Select Negotiated Service Agreement, 890 2022-28652 Priority Mail and Parcel Select Negotiated Service Agreement, 890 2022-28646 Priority Mail Express, Priority Mail, First-Class Package Service, and Parcel Select Service Negotiated Service Agreement, 890-891 2022-28645 Priority Mail, First-Class Package Service and Parcel Select Negotiated Service Agreement, 891 2022-28649 2022-28650 Priority Mail, Parcel Select and Parcel Return Service Negotiated Service Agreement, 891 2022-28647 Presidential Documents Presidential Documents PROCLAMATIONS Special Observances:

National Human Trafficking Prevention Month (Proc. 10510), 739-740 2023-00092 National Mentoring Month (Proc. 10511), 741-742 2023-00093 National Stalking Awareness Month (Proc. 10512), 743-744 2023-00094 Securities Securities and Exchange Commission NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals: Customer Account Statements, 893-894 2022-28600 Application: Deregistration under the Investment Company Act, 896-897 2022-28642 Self-Regulatory Organizations;

Proposed Rule Changes: New York Stock Exchange LLC, 894-896 2022-28598 The Nasdaq Stock Market LLC, 892-893 2022-28599 State Department State Department NOTICES Culturally Significant Object Being Imported for Exhibition: Death is Not the End, 897 2022-28638 From Depero to Rotella: Italian Commercial Posters between Advertising and Art, 897 2022-28637 Monet/Mitchell: Painting the French Landscape, 898 2022-28625 Surface Transportation Surface Transportation Board NOTICES Acquisition of Control:

Transdev Group, S.A., First Transit Topco, Inc.;, 898-899 2022-28607 Exemption: Acquisition and Operation; Colorado Pacific Rio Grande Railroad, LLC, San Luis and Rio Grande Railroad, Inc., 899-900 2022-28644 Transportation Department Transportation Department See Federal Aviation Administration See Federal Motor Carrier Safety Administration See Pipeline and Hazardous Materials Safety Administration Treasury Treasury Department See Internal Revenue Service Veteran Affairs Veterans Affairs Department NOTICES Privacy Act;

Systems of Records, 911-913 2022-28643 Separate Parts In This Issue Part II Commerce Department, National Oceanic and Atmospheric Administration, 916-948 2022-28208 Reader Aids Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, and notice of recently enacted public laws. To subscribe to the Federal Register Table of Contents electronic mailing list, go to https://public.govdelivery.com/accounts/USGPOOFR/subscriber/new, enter your e-mail address, then follow the instructions to join, leave, or manage your subscription. 88 3 Thursday, January 5, 2023 Rules and Regulations DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 172 [Docket No.

FDA-2019-F-3519] Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D 3 AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. SUMMARY: The Food and Drug Administration (FDA or we) is amending the food additive regulations to provide for the safe use of vitamin D 3 as a nutrient supplement in breakfast cereals and grain-based bars ( *e.g.,* breakfast bars, granola bars, rice cereal bars), and to update the reference for the Vitamin D 3 specifications.

We are taking this action in response to a petition filed by Kellogg Company (Kellogg). DATES: This rule is effective January 5, 2023. The incorporation by reference of certain material listed in the rule is approved by the Director of the Federal Register as of January 5, 2023. See section VIII for further information on the filing of objections. Either electronic or written objections and requests for a hearing on the final rule must be submitted by February 6, 2023. ADDRESSES:

You may submit objections and requests for a hearing as follows. Please note that late, untimely filed objections will not be considered. The *https://www.regulations.gov* electronic filing system will accept objections until 11:59 p.m. Eastern Time at the end of February 6, 2023. Objections received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date. Electronic Submissions Submit electronic objections in the following way: • *Federal eRulemaking Portal: https://www.regulations.gov* .

Follow the instructions for submitting comments. Objections submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your objection will be made public, you are solely responsible for ensuring that your objection does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process.

Please note that if you include your name, contact information, or other information that identifies you in the body of your objection, that information will be posted on *https://www.regulations.gov* . • If you want to submit an objection with confidential information that you do not wish to be made available to the public, submit the objection as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”). Written/Paper Submissions Submit written/paper submissions as follows: • *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper objections submitted to the Dockets Management Staff, FDA will post your objection, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.” *Instructions:* All submissions received must include the Docket No.

FDA-2019-F-3519 for “Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D 3 .” Received objections, those filed in a timely manner (see ADDRESSES ), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500. • Confidential Submissions—To submit an objection with confidential information that you do not wish to be made publicly available, submit your objections only as a written/paper submission.

You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” We will review this copy, including the claimed confidential information, in our consideration of objections. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov* . Submit both copies to the Dockets Management Staff.

If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your objections and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf* . *Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Lane A. Highbarger, Center for Food Safety and Applied Nutrition (HFS-255), Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740-3835, 240-402-1204, or Joan Rothenberg, Center for Food Safety and Applied Nutrition, Office of Regulations and Policy (HFS-024), Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-2378. SUPPLEMENTARY INFORMATION: I. Background In the **Federal Register** of August 12, 2019 (84 FR 39785), we announced that we filed a food additive petition (FAP 9A4823) submitted on behalf of Kellogg by Hogan Lovells US LLP, Columbia Square, 555 Thirteenth St.

NW, Washington, DC 20004. The petition proposed that FDA amend the food additive regulations in § 172.380 (21 CFR 172.380) to provide for the safe use of vitamin D 3 as a nutrient supplement in:

(1)breakfast cereals as defined in § 170.3(n)(4) (21 CFR 170.3(n)(4)) at levels up to 560 international units

(IU)vitamin D 3 per 100 grams

(g)and

(2)grain-based nutrition bars at levels up to 400 IU vitamin D 3 per 100 g. (One IU of vitamin D is equivalent to 0.025 micrograms (µg) of vitamin D. We also note that while the petition uses “grain-based nutrition bars,” we consider this to refer to the same category of food products as “grain-based bars” ( *e.g.,* breakfast bars, granola bars, rice cereal bars), which is used elsewhere in existing FDA regulations (see 21 CFR 172.780 and 101.12); therefore, for consistency of terminology, we are using “grain-based bars.”) FDA is also updating the reference for specifications for vitamin D 3 established in § 172.380(b) by incorporating by reference the most recent edition of the Food Chemicals Codex (FCC). The current food additive regulation for the use of vitamin D 3 (§ 172.380) indicates that the additive must meet the specifications in the 11th edition of the FCC (FCC 11). Since we received the petition, the FCC has been updated to the 13th edition (FCC 13). The specifications for Vitamin D 3 from FCC 11 are identical to those in FCC 13. Therefore, we are amending § 172.380(b) by adopting, and incorporating by reference, the most recent edition of the FCC (FCC 13). Vitamin D is essential for human health. The major function of vitamin D is the maintenance of blood serum concentrations of calcium and phosphorus by enhancing the absorption of these minerals in the small intestine. Vitamin D deficiency can lead to abnormalities in calcium and bone metabolism, such as rickets in children or osteomalacia in adults. At high levels in the diet, vitamin D may be toxic. Excessive intake of vitamin D elevates blood plasma calcium levels (hypercalcemia) by increased intestinal absorption and/or mobilization from the bone, and possibly associated with decreased renal function and increased cardiovascular risk (Refs. 1 and 2). To ensure that vitamin D is not added to the U.S. food supply at levels that could raise safety concerns, FDA affirmed vitamin D as generally recognized as safe

(GRAS)with specific limitations as listed in § 184.1950 (21 CFR 184.1950). Under § 184.1(b)(2) (21 CFR 184.1(b)(2)), an ingredient affirmed as GRAS with specific limitations may be used in food only within such limitations, including the category of food, functional use of the ingredient, and level of use. Any addition of vitamin D to food beyond those limitations set out in § 184.1950 requires a food additive regulation. Vitamin D comprises a group of fat-soluble seco-sterols and occurs in many forms. The two major physiologically relevant forms are vitamin D 2 and vitamin D 3 . Vitamin D without a subscript represents vitamin D 2 , vitamin D 3 , or both. Vitamin D is affirmed as GRAS for use in certain foods as a nutrient supplement (as defined under § 170.3(o)(20)) under § 184.1950(c)(1), in accordance with § 184.1(b)(2), as the sole source of added vitamin D only within the following specific limitations: Category of food Maximum levels in food (as served) (IU/100 g) Breakfast cereals 350 Grain products and pasta 90 Milk 42 Milk products 89 Vitamin D is also affirmed as GRAS under § 184.1950(c)(2) and

(3)for use in infant formula and margarine, respectively. Vitamin D 2 is an approved food additive under § 172.379 (21 CFR 172.379) for use as a nutrient supplement in edible plant-based beverages intended as milk alternatives, edible plant-based yogurt alternatives, soy beverage products, soy-based butter substitute spreads, and soy-based cheese substitutes and soy-based cheese substitute products. Vitamin D 3 is an approved food additive under § 172.380 for use as a nutrient supplement in certain calcium-fortified 100 percent fruit juices and fruit juice drinks; meal replacement and other-type bars that are represented for special dietary use in reducing or maintaining body weight; soy-protein based meal replacement beverages that are represented for special dietary use in reducing or maintaining body weight; certain cheese and cheese products; certain meal replacement beverages that are not intended for special dietary use in reducing or maintaining body weight; foods represented for use as a sole source of nutrition for enteral feeding; and milk that contains more than 42 IU vitamin D per 100 g and that meets the requirements for foods named by use of a nutrient content claim and a standardized term in accordance with 21 CFR 130.10. Vitamin D 2 baker's yeast is an approved food additive under § 172.381 (21 CFR 172.381) for use as a source of vitamin D 2 and as a leavening agent in yeast-leavened baked goods and baking mixes, and yeast-leavened baked snack foods. Vitamin D 2 mushroom powder is an approved food additive under § 172.382 (21 CFR 172.382) for use as a source of vitamin D 2 in foods to which vitamin D 2 , vitamin D 3 , and vitamin D 2 baker's yeast are currently allowed to be added under §§ 184.1950, 172.379, 172.380, and 172.381, excluding cheese and cheese products, foods represented for use as a sole source of nutrition for enteral feeding, infant formula, milk and milk products, and margarine; fruit smoothies; vegetable juices; extruded vegetable snacks; certain soups and soup mixes; and plant protein products. To support their petition, Kellogg submitted dietary exposure estimates of vitamin D from the proposed uses of vitamin D 3 , as well as all naturally occurring dietary sources of vitamin D, currently approved and affirmed uses of vitamin D under our food additive and GRAS regulations, and dietary supplements. Kellogg compared these dietary exposure estimates to the Tolerable Upper Intake Level

(UL)for vitamin D established by the Institute of Medicine

(IOM)of the National Academies (now the National Academy of Medicine). Kellogg also submitted published scientific literature pertaining to human clinical studies on vitamin D. II. Evaluation of Safety To establish with reasonable certainty that a food additive is not harmful under its intended conditions of use, we consider the projected human dietary exposure to the additive, the additive's toxicological data, and other relevant information (such as published scientific literature) available to us. We compare the dietary exposure for the additive from all food sources to an acceptable intake level established by data. The dietary exposure is determined based on the amount of the additive proposed for specific uses in foods and on data regarding the amount consumed from all food sources of the additive. We commonly use the dietary exposure for the 90th percentile consumer of a food additive as a measure of high chronic dietary exposure (Ref. 3). A. Acceptable Daily Intake for Vitamin D In 2011, the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes of the Food and Nutrition Board at the IOM conducted an extensive review of relevant published scientific literature to update established dietary reference intakes

(DRI)for vitamin D; these DRIs are a family of nutrient reference values that includes ULs (Ref. 4). Based on this information, the IOM revised the ULs for vitamin D and published a report on their findings (Ref. 5). In their 2011 assessment of vitamin D, the IOM established the following ULs for different age groups, including total consumption from food, including dietary supplements and water: UL IU/per person/day (p/d) Age group 1,000 infants 0 months to 6 months of age. 1,500 infants 6 months to 12 months of age. 2,500 children 1-3 years of age. 3,000 children 4-8 years of age. 4,000 adolescents aged 9-18 years of age and adults. The IOM considers the UL as the maximum daily intake level of a nutrient that is likely to pose no health hazard risk for almost all individuals in the general population when the nutrient is consumed over long periods of time. The UL is determined using a risk assessment approach developed specifically for nutrients. The dose-response assessment, which concludes with an estimate of the UL, is built upon three toxicological concepts commonly used in assessing the risk of exposures to chemical substances: no-observed-adverse-effect level, lowest-observed-effect level, and application of an uncertainty factor. We considered the ULs established by the IOM relative to the cumulative dietary exposure estimates as the primary basis for assessing the safety of the petitioned uses of vitamin D 3 . We also reviewed published scientific literature on the safety of vitamin D submitted in the petition, as well as other relevant published studies available to FDA. B. Dietary Exposure Estimate for Vitamin D Kellogg provided mean and 90th percentile eaters-only dietary exposure estimates for vitamin D for the overall U.S. population and eight population subgroups from the:

(1)proposed uses of vitamin D 3 ;

(2)current food sources of vitamin D (including approved food additive and affirmed GRAS uses as a food ingredient, naturally occurring sources of vitamin D, and dietary supplements); and

(3)the combined current and proposed food uses. Kellogg noted that dietary exposure was not estimated for infants 0-6 months as this age group is not expected to consume breakfast cereals or grain-based bars. Additionally, Kellogg indicated that dietary exposure was not estimated for infants 6-12 months for grain-based bars for the same reason; however, they were included in the exposure estimate for breakfast cereals (Ref. 3). Kellogg presented the dietary exposure estimates to vitamin D from the proposed and existing uses. However, Kellogg did not provide an overall dietary exposure from all proposed uses, but instead provided separate dietary exposures for each of the petitioned uses of vitamin D 3 . Kellogg then estimated a cumulative dietary exposure to vitamin D by adding the dietary exposures from each of the proposed uses and that from the existing uses. While the estimates of dietary exposures to each of the proposed and the existing uses of vitamin D are important to consider, it is not appropriate to estimate a cumulative dietary exposure by summing all the values because the populations of consumers for each of the food uses are not the same. Additionally, since the submission of the current petition by Kellogg, vitamin D 2 mushroom powder was approved under § 172.382 for use as a source of vitamin D 2 in certain foods (see Section I. Background). As a result, Kellogg did not include these uses in its cumulative dietary exposure estimate. Therefore, FDA conducted dietary exposure estimates to determine:

(1)the overall dietary exposure to vitamin D 3 from the petitioned uses and

(2)a cumulative dietary exposure for vitamin D from all existing sources, including the approved uses of vitamin D 2 in mushroom powder, and the petitioned uses for vitamin D 3 (Ref. 3). FDA performed the dietary exposure estimate for vitamin D 3 from the proposed uses in breakfast cereals and grain-based bars using the combined 2011-2014 National Health and Nutrition Examination Survey. FDA also estimated a cumulative dietary exposure for vitamin D that includes all existing sources of vitamin D ( *i.e.,* naturally occurring sources, approved and affirmed GRAS food uses of vitamin D, and dietary supplements) and Kellogg's proposed uses for vitamin D 3 in breakfast cereals and grain-based bars. Furthermore, FDA also included dietary exposure to the vitamin D metabolite, 25-hydroxyvitamin D, in the cumulative estimate to account for discrepancies seen between dietary intake and blood serum levels of vitamin D (Ref. 3). For the overall U.S. population 1 year of age and older, we estimated the cumulative dietary exposure at the 90th percentile from all food sources of vitamin D, including the proposed uses and background sources, to be 2,730 IU/p/d. Additionally, the estimated 90th percentile dietary exposure to vitamin D from all food sources for infants 6 to 12 months of age is 1,060 IU/p/d. In summary, the cumulative dietary exposure to vitamin D 3 at the 90th percentile from the petitioned and background sources is below the IOM UL for all population groups for which ULs were established. C. Safety of the Petitioned Uses of Vitamin D 3 We reviewed and evaluated the information submitted by Kellogg regarding the safety of the dietary exposure to vitamin D 3 from the proposed uses in grain-based bars and breakfast cereals. Kellogg submitted reports of scientific studies published after the 2011 IOM report and concluded that these publications support a conclusion that the proposed uses of vitamin D 3 are safe. We reviewed the published reports of scientific studies on vitamin D submitted by Kellogg, as well as other relevant published studies available to us since our previous evaluations of food additive petitions for fortifying a variety of foods with vitamin D (85 FR 41916, July 13, 2020; 81 FR 46578, July 18, 2016; 79 FR 46993, August 12, 2014; 77 FR 52228, August 29, 2012; 74 FR 11019, March 16, 2009; 70 FR 69435, November 16, 2005; 70 FR 37255, June 29, 2005; 70 FR 36021, June 22, 2005; 68 FR 9000, February 27, 2003). These studies did not raise any new safety concerns regarding the current or proposed uses of vitamin D. The most recent food additive petition for a new use of vitamin D resulted in our amendment of the food additive regulations in § 172.382 to allow for the safe use of vitamin D 2 mushroom powder in specific food categories (85 FR 41916). The earlier food additive petitions also resulted in amendments of the food additive regulations to allow for the safe use of vitamin D as a nutrient supplement in certain foods. We consider the ULs established by the IOM relative to the dietary exposure estimates as the primary basis for assessing the safety of the petitioned uses of vitamin D 3 . Depending on the age group, the IOM ULs for vitamin D for the U.S. population 4 years and older range from 3,000 IU/p/d to 4,000 IU/p/d. FDA's cumulative dietary exposure estimate for vitamin D from all food sources, including the proposed uses, at the 90th percentile for the U.S. population 1 year of age and older is estimated to be no greater than 2,740 IU/p/d, which is below the IOM ULs for all population groups 4 years and above. Estimated dietary exposure to vitamin D from all food sources for infants 6 months to 12 months of age is 1,060 IU/p/d, and for children aged 1 year to 3 years old is 1,730 IU/p/d. These estimates are below the respective IOM UL of 1,500 IU/p/d for infants 6 months to 12 months of age, and 2,500 IU/p/d for children aged older than 1 year to 3 years old (Ref. 6). Because the estimated 90th percentile dietary exposure to vitamin D from all current and proposed food uses for each population group is less than the corresponding IOM UL for that population group, we conclude that dietary exposure to vitamin D 3 from the proposed uses as a nutrient supplement in breakfast cereals and grain-based bars are safe (Ref. 6). III. Conclusion Based on the relevant data available to FDA and information in the petition, we conclude that there is a reasonable certainty that no harm will result from the use of vitamin D 3 as a nutrient supplement in breakfast cereals, as defined in § 170.3(n)(4), at a level up to 560 IU vitamin D 3 per 100 g and in grain-based bars at a level up to 400 IU vitamin D 3 per 100 g. Additionally, we are amending § 172.380(b) by adopting, and incorporating by reference, the most recent edition of the FCC (FCC 13). IV. Incorporation by Reference FDA is incorporating by reference the monograph for vitamin D 3 from the Food Chemicals Codex, 13th ed., 2022, which was approved by the Office of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may purchase a copy of the material from the U.S. Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852, 1-800-227-8772, *https://www.usp.org/.* You may inspect a copy at Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday. On our own initiative, we have revised § 172.380 to state that the referenced material can be found at FDA's Dockets Management Staff instead of FDA's Main Library. This change reflects a recent decision regarding the location of referenced materials cited in FDA regulations. The FCC monograph sets forth a standard for purity and identity for vitamin D 3 . The monograph provides specifications and analytical methodologies to identify the substance and establish acceptable purity criteria. The current food additive regulation for the use of vitamin D 3 (§ 172.380) indicates that the additive must meet the specifications in the FCC 11. The petitioner indicated that the vitamin D 3 petitioned in FAP 9A4823 complies with the specifications in the monograph for vitamin D 3 in FCC 11. Since we received the petition, the FCC has been updated to the 13th edition (FCC 13). The specifications for vitamin D 3 in FCC 13 are identical to those in FCC 11. Therefore, we are amending § 172.380(b) by adopting, and incorporating by reference, the specifications for vitamin D 3 in FCC 13 in place of FCC 11. V. Public Disclosure In accordance with § 171.1(h) (21 CFR 171.1(h)), the petition and the documents that we considered and relied upon in reaching our decision to approve the petition will be made available for public disclosure (see FOR FURTHER INFORMATION CONTACT ). As provided in § 171.1(h), we will delete from the documents any materials that are not available for public disclosure. VI. Analysis of Environmental Impact We previously considered the environmental effects of this rule, as stated in the August 12, 2019, **Federal Register** notice of petition for FAP 9A4823 (84 FR 39785). We stated that we had determined, under 21 CFR 25.32(k), that this action is of a type that does not individually or cumulatively have a significant effect on the human environment such that neither an environmental assessment nor an environmental impact statement is required. We have not received any new information or comments that would affect our previous determination. VII. Paperwork Reduction Act of 1995 This final rule contains no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required. VIII. Objections If you will be adversely affected by one or more provisions of this regulation, you may file with the Dockets Management Staff (see ADDRESSES ) either electronic or written objections. You must separately number each objection, and within each numbered objection you must specify with particularity the provision(s) to which you object, and the grounds for your objection. Within each numbered objection, you must specifically state whether you are requesting a hearing on the particular provision that you specify in that numbered objection. If you do not request a hearing for any particular objection, you waive the right to a hearing on that objection. If you request a hearing, your objection must include a detailed description and analysis of the specific information you intend to present in support of the objection in the event that a hearing is held. If you do not include such a description and analysis for any particular objection, you waive the right to a hearing on the objection. Any objections received in response to the regulation may be seen in the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at *https:/www.regulations.gov.* IX. Section 301(ll) of the Federal Food, Drug, and Cosmetic Act Our review of this petition was limited to section 409 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 348). This final rule is not a statement regarding compliance with other sections of the FD&C Act. For example, section 301(ll) of the FD&C Act (21 U.S.C. 331(ll)) prohibits the introduction or delivery for introduction into interstate commerce of any food that contains a drug approved under section 505 of the FD&C Act (21 U.S.C. 355), a biological product licensed under section 351 of the Public Health Service Act (42 U.S.C. 262), or a drug or biological product for which substantial clinical investigations have been instituted and their existence has been made public, unless one of the exemptions in section 301(ll)(1) through

(4)of the FD&C Act applies. In our review of this petition, we did not consider whether section 301(ll) of the FD&C Act or any of its exemptions apply to food containing this additive. Accordingly, this final rule should not be construed to be a statement that a food containing this additive, if introduced or delivered for introduction into interstate commerce, would not violate section 301(ll) of the FD&C Act. Furthermore, this language is included in all food additive final rules and therefore should not be construed to be a statement of the likelihood that section 301(ll) of the FD&C Act applies. X. References The following references marked with an asterisk (*) are on display in the Dockets Management Staff (see ADDRESSES ) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at *https://www.regulations.gov.* References without asterisks are not on public display at *https://www.regulations.gov* because they have copyright restriction. Some may be available at the website address, if listed. References without asterisks are available for viewing only at the Dockets Management Staff. FDA has verified the website addresses, as of the date this document publishes in the **Federal Register** , but websites are subject to change over time. * 1. National Institutes of Health, Office of Dietary Supplements, “Vitamin D—Fact Sheet for Consumers,” 2021. Available at: *https://ods.od.nih.gov/factsheets/Vitamind-Consumer/.* 2. Pilz, S., W. Marz, K.D. Cashman, et al., “Rationale and Plan for Vitamin D Food Fortification: A Review and Guidance Paper,” *Frontiers in Endocrinology,* 9, 2018. Available at: *https://www.frontiersin.org/articles/10.3389/fendo.2018.00373/full.* * 3. FDA Memorandum from R. Shah, Chemistry Review Branch, Division of Food Ingredients, to L. Highbarger, Regulatory Review Branch, Division of Food Ingredients, October 13, 2022. * 4. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross, A.C., C.L. Taylor, A.L. Yaktine, et al., editors. “Dietary Reference Intakes for Calcium and Vitamin D.” Washington (DC): National Academies Press, 2011. Available at: *https://www.ncbi.nlm.nih.gov/books/NBK56070/* . 5. Taylor, C., K. Patterson, J. Roseland, et al., “Including Food 25-Hydroxyvitamin D in Intake Estimates May Reduce the Discrepancy between Dietary and Serum Measures of Vitamin D Status.” *Journal of Nutrition,* 144: 654-659, 2014. Available at: *https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985821/pdf/nut144654.pdf.* * 6. FDA Memorandum from S.A. Assimon, Toxicology Review Branch, Division of Food Ingredients, to L. Highbarger, Regulatory Review Branch, Division of Food Ingredients, October 14, 2022. List of Subjects in 21 CFR Part 172 Food additives, Incorporation by reference, Reporting and recordkeeping requirements. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 172 is amended as follows: PART 172—FOOD ADDITIVES PERMITTED FOR DIRECT ADDITION TO FOOD FOR HUMAN CONSUMPTION 1. The authority citation for part 172 continues to read as follows: Authority: 21 U.S.C. 321, 341, 342, 348, 371, 379e. 2. Amend § 172.380 by revising paragraph

(b)and adding paragraphs (c)(9) and

(10)to read as follows: § 172.380 Vitamin D 3 .

(b)Vitamin D 3 meets the specifications of “Vitamin D 3 ,” *Food Chemicals Codex,* 13th edition, effective June 1, 2022, which is incorporated by reference. The Director of the Office of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the U.S. Pharmacopeial Convention, 12601 Twinbrook Pkwy., Rockville, MD 20852; website: *https://www.usp.org.* Copies may be examined at the FDA or the National Archives and Records Administration (NARA). Contact FDA at: the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500. For information on inspecting this material at NARA, visit *www.archives.gov/federal-register/cfr/ibr-locations.html* or email *fr.inspection@nara.gov.*

(c)* * *

(9)At levels not to exceed 560 IU per 100 g in breakfast cereals (as defined under § 170.3(n)(4) of this chapter).

(10)At levels not to exceed 400 IU per 100 g in grain-based bars ( *e.g.,* breakfast bars, granola bars, rice cereal bars). Dated: December 27, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022-28428 Filed 1-4-23; 8:45 am]

Connectionstraces to 18

Traces to 18 documents

CFR